GB2478595B - Phytocannabinoids in the treatment of glioma - Google Patents

Phytocannabinoids in the treatment of glioma

Info

Publication number
GB2478595B
GB2478595B GB1004137.4A GB201004137A GB2478595B GB 2478595 B GB2478595 B GB 2478595B GB 201004137 A GB201004137 A GB 201004137A GB 2478595 B GB2478595 B GB 2478595B
Authority
GB
United Kingdom
Prior art keywords
phytocannabinoids
glioma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1004137.4A
Other languages
English (en)
Other versions
GB2478595A (en
GB201004137D0 (en
Inventor
Parolaro Daniela
Massi Paola
Antonio Izzo Angelo
Borelli Francesca
Aviello Gabriella
Di Marzo Vincenzo
De Petrocellis Luciano
Schiano Moriello Aniello
Ligresti Alessia
Alexandra Ross Ruth
Ann Ford Lesley
Anavi-Goffer Sharon
Guzman Pastor Manuel
Velasco Guillermo
Lorente Mar
Torres Sofia
Kikuchi Tetsuro
William Guy Geoffrey
Stott Colin
Wright Stephen
Sutton Alan
Potter David
De Meijer Etienne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42261478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2478595(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Priority to GB1718726.1A priority Critical patent/GB2554592B/en
Priority to GB1004137.4A priority patent/GB2478595B/en
Publication of GB201004137D0 publication Critical patent/GB201004137D0/en
Priority to ARP110100670A priority patent/AR080454A1/es
Priority to TW100107897A priority patent/TWI461205B/zh
Priority to AU2011225837A priority patent/AU2011225837A1/en
Priority to US13/634,343 priority patent/US8790719B2/en
Priority to CA2792722A priority patent/CA2792722A1/en
Priority to HRP20160427TT priority patent/HRP20160427T1/hr
Priority to MX2012010512A priority patent/MX2012010512A/es
Priority to CN2011800236521A priority patent/CN102869356A/zh
Priority to BR112012023017A priority patent/BR112012023017A8/pt
Priority to EA201290901A priority patent/EA201290901A1/ru
Priority to UAA201211775A priority patent/UA109271C2/uk
Priority to PL11709175T priority patent/PL2544682T3/pl
Priority to ES11709175.1T priority patent/ES2569669T3/es
Priority to SG2012067393A priority patent/SG184016A1/en
Priority to KR1020127026659A priority patent/KR20130067248A/ko
Priority to DK11709175.1T priority patent/DK2544682T3/en
Priority to PH1/2012/501782A priority patent/PH12012501782A1/en
Priority to JP2012556592A priority patent/JP5785569B2/ja
Priority to PCT/GB2011/050487 priority patent/WO2011110866A1/en
Priority to EP11709175.1A priority patent/EP2544682B1/en
Priority to NZ602953A priority patent/NZ602953A/en
Priority to NZ629136A priority patent/NZ629136A/en
Priority to SI201130799A priority patent/SI2544682T1/sl
Priority to HUE11709175A priority patent/HUE029817T2/en
Publication of GB2478595A publication Critical patent/GB2478595A/en
Priority to IL221871A priority patent/IL221871A/en
Priority to CO12177686A priority patent/CO6630103A2/es
Priority to ZA2012/07574A priority patent/ZA201207574B/en
Priority to US14/260,876 priority patent/US9675654B2/en
Priority to CY20161100356T priority patent/CY1117451T1/el
Priority to AU2016266059A priority patent/AU2016266059A1/en
Priority to US15/620,435 priority patent/US20180042975A1/en
Publication of GB2478595B publication Critical patent/GB2478595B/en
Application granted granted Critical
Priority to AU2018217273A priority patent/AU2018217273B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1004137.4A 2010-03-12 2010-03-12 Phytocannabinoids in the treatment of glioma Active GB2478595B (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GB1718726.1A GB2554592B (en) 2010-03-12 2010-03-12 A glioma treatment Comprising Temozolomide with a mixture of THA and CBD ar a ration of 1:1
GB1004137.4A GB2478595B (en) 2010-03-12 2010-03-12 Phytocannabinoids in the treatment of glioma
ARP110100670A AR080454A1 (es) 2010-03-12 2011-03-03 Fitocanabinoides en el tratamiento del cancer
TW100107897A TWI461205B (zh) 2010-03-12 2011-03-09 治療癌症之植物大麻素
HUE11709175A HUE029817T2 (en) 2010-03-12 2011-03-11 Phytocannabinoids for cancer treatment
DK11709175.1T DK2544682T3 (en) 2010-03-12 2011-03-11 PHYTOCANNABINOIDS IN CANCER TREATMENT
EP11709175.1A EP2544682B1 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
CA2792722A CA2792722A1 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
HRP20160427TT HRP20160427T1 (hr) 2010-03-12 2011-03-11 Fitokanabinoidi u liječenju raka
MX2012010512A MX2012010512A (es) 2010-03-12 2011-03-11 Fitocannabinoides en el tratamiento del cancer.
CN2011800236521A CN102869356A (zh) 2010-03-12 2011-03-11 治疗癌症中的植物大麻素
BR112012023017A BR112012023017A8 (pt) 2010-03-12 2011-03-11 Fitocanabinóides no tratamento de câncer.
EA201290901A EA201290901A1 (ru) 2010-03-12 2011-03-11 Фитоканнабиноиды для лечения злокачественной опухоли
UAA201211775A UA109271C2 (uk) 2010-03-12 2011-03-11 Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
PL11709175T PL2544682T3 (pl) 2010-03-12 2011-03-11 Fitokannabinoidy w leczeniu glejaka
ES11709175.1T ES2569669T3 (es) 2010-03-12 2011-03-11 Fitocannabinoides en el tratamiento del cáncer
SG2012067393A SG184016A1 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
KR1020127026659A KR20130067248A (ko) 2010-03-12 2011-03-11 암의 치료에서 파이토칸나비노이드
AU2011225837A AU2011225837A1 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
PH1/2012/501782A PH12012501782A1 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
JP2012556592A JP5785569B2 (ja) 2010-03-12 2011-03-11 がんの治療におけるフィトカンナビノイド
PCT/GB2011/050487 WO2011110866A1 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
US13/634,343 US8790719B2 (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
NZ602953A NZ602953A (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
NZ629136A NZ629136A (en) 2010-03-12 2011-03-11 Phytocannabinoids in the treatment of cancer
SI201130799A SI2544682T1 (sl) 2010-03-12 2011-03-11 Fitokanabinoidi pri zdravljenju raka
IL221871A IL221871A (en) 2010-03-12 2012-09-10 Use of a medicament containing tetrahydrocannabinol, cannabidiol and temozolomide in the treatment of glioma
ZA2012/07574A ZA201207574B (en) 2010-03-12 2012-10-09 Phytocannabinoids in the treatment of cancer
CO12177686A CO6630103A2 (es) 2010-03-12 2012-10-09 Fitocanabinoides en el tratamiento de cáncer
US14/260,876 US9675654B2 (en) 2010-03-12 2014-04-24 Phytocannabinoids in the treatment of cancer
CY20161100356T CY1117451T1 (el) 2010-03-12 2016-04-27 Φυτο-κανναβινοειδη στην θεραπεια του καρκινου
AU2016266059A AU2016266059A1 (en) 2010-03-12 2016-12-01 Phytocannabinoids in the treatment of cancer
US15/620,435 US20180042975A1 (en) 2010-03-12 2017-06-12 Phytocannabinoids in the treatment of cancer
AU2018217273A AU2018217273B2 (en) 2010-03-12 2018-08-16 Phytocannabinoids in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1004137.4A GB2478595B (en) 2010-03-12 2010-03-12 Phytocannabinoids in the treatment of glioma

Publications (3)

Publication Number Publication Date
GB201004137D0 GB201004137D0 (en) 2010-04-28
GB2478595A GB2478595A (en) 2011-09-14
GB2478595B true GB2478595B (en) 2018-04-04

Family

ID=42261478

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1004137.4A Active GB2478595B (en) 2010-03-12 2010-03-12 Phytocannabinoids in the treatment of glioma

Country Status (28)

Country Link
US (3) US8790719B2 (enExample)
EP (1) EP2544682B1 (enExample)
JP (1) JP5785569B2 (enExample)
KR (1) KR20130067248A (enExample)
CN (1) CN102869356A (enExample)
AR (1) AR080454A1 (enExample)
AU (3) AU2011225837A1 (enExample)
BR (1) BR112012023017A8 (enExample)
CA (1) CA2792722A1 (enExample)
CO (1) CO6630103A2 (enExample)
CY (1) CY1117451T1 (enExample)
DK (1) DK2544682T3 (enExample)
EA (1) EA201290901A1 (enExample)
ES (1) ES2569669T3 (enExample)
GB (1) GB2478595B (enExample)
HR (1) HRP20160427T1 (enExample)
HU (1) HUE029817T2 (enExample)
IL (1) IL221871A (enExample)
MX (1) MX2012010512A (enExample)
NZ (2) NZ629136A (enExample)
PH (1) PH12012501782A1 (enExample)
PL (1) PL2544682T3 (enExample)
SG (1) SG184016A1 (enExample)
SI (1) SI2544682T1 (enExample)
TW (1) TWI461205B (enExample)
UA (1) UA109271C2 (enExample)
WO (1) WO2011110866A1 (enExample)
ZA (1) ZA201207574B (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
EP1811983B1 (en) 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2494461A (en) * 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
WO2013164824A1 (en) 2012-05-03 2013-11-07 Magdent Ltd. Bone enhancement device and method
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
IL240830B (en) * 2013-02-28 2022-08-01 Teewinot Tech Limited Processes for chemical engineering and the device for the synthesis of compounds
EP4137142A1 (en) 2013-03-14 2023-02-22 Purple Mundo, Inc. Bioactive concentrates and uses thereof
US10441617B2 (en) 2013-03-15 2019-10-15 Biotech Institute, Llc Breeding, production, processing and use of medical cannabis
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
GB2513167B (en) * 2013-04-18 2016-03-02 Otsuka Pharma Co Ltd Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
GB2515312A (en) * 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US10774288B2 (en) * 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
KR20160094950A (ko) * 2013-10-31 2016-08-10 풀 스펙트럼 래버러토리즈, 리미티드 테르펜 및 칸나비노이드 제제
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
EP3171871B1 (en) 2014-07-21 2024-10-23 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
BR112017003966A2 (pt) 2014-08-25 2018-10-23 Full Spectrum Laboratories Ltd aparelhos e métodos para a produção simultânea de compostos canabinoides
WO2016044370A1 (en) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US9730911B2 (en) * 2014-10-21 2017-08-15 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
CN104277917B (zh) * 2014-10-24 2018-02-09 汉康(云南)生物科技有限公司 一种富含大麻二酚的工业大麻精油提取方法及其提取设备
US10502750B2 (en) 2014-12-23 2019-12-10 Biotech Institute, Llc Reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10830780B2 (en) 2015-01-26 2020-11-10 Biotech Institute, Llc Apparatus and methods for sample analysis and classification based on terpenes and cannabinoids in the sample
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
MX386351B (es) 2015-01-31 2025-03-18 Constance Therapeutics Inc Métodos para la preparación de extractos y composiciones de aceite de cannabis.
MX2017010872A (es) 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
AU2016258208B2 (en) * 2015-05-07 2021-05-27 Mark Andrew Scialdone Hydrogenation of cannabis oil
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3319446A4 (en) * 2015-07-06 2019-07-03 Cg- Bio Genomics, Inc. Healthful supplements
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017091764A1 (en) * 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
BR112018068986B1 (pt) * 2016-03-18 2023-03-21 Christopher Brian Reid Composição para reduzir a expressão oncógena de uma célula, tecido ou órgão de um indivíduo
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
PE20200676A1 (es) * 2016-08-03 2020-06-11 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis
MX386086B (es) * 2016-08-03 2025-03-18 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
WO2018044953A1 (en) 2016-08-29 2018-03-08 Ebbu, LLC Water soluble compositions comprising purified cannabinoids
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CA3054690A1 (en) * 2017-03-01 2018-09-07 Canopy Growth Corporation Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
CN110799186A (zh) 2017-03-05 2020-02-14 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 治疗炎性疾病的组合物和方法
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
CA3064563A1 (en) 2017-05-22 2018-11-29 Gbs Global Biopharma, Inc. Myrcene-containing complex mixtures targeting trpv1
WO2018232448A1 (en) 2017-06-19 2018-12-27 Zelda Therapeutics Operations Pty Ltd COMPOSITION AGAINST SLEEP APNEA AND RELATED TREATMENTS
WO2018235079A1 (en) 2017-06-20 2018-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CA3068383A1 (en) * 2017-06-28 2019-01-03 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid product for women health
CN111629724A (zh) * 2017-09-02 2020-09-04 科学控股公司 四氢大麻酚调节剂
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CN108204786A (zh) * 2018-01-15 2018-06-26 武汉盛硕电子有限公司 一种基于手机模块的北斗测量系统
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
US20210038559A1 (en) * 2018-01-22 2021-02-11 Thomas Richard Gadek Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
CA3225993A1 (en) * 2018-02-08 2019-08-15 University Of Southern California The use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier
KR20190098649A (ko) 2018-02-14 2019-08-22 (주)카이언바이오텍 칸나비디올 추출물을 함유하는 대장암 예방 또는 치료용 약학 조성물
KR102041875B1 (ko) 2018-02-14 2019-11-08 (주)카이언바이오텍 대마로부터 추출된 칸나비디올 추출물 및 트레일을 함유하는 대장암 예방 또는 치료용 약학 조성물
CA3091776C (en) * 2018-02-20 2021-12-28 Supera Pharmaceuticals, Inc. Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders
BR112020019768A2 (pt) 2018-03-30 2021-01-26 India Globalization Capital, Inc. método e composição para o tratamento de distúrbios do sistema nervoso central (snc)
CA3095970A1 (en) 2018-04-04 2019-10-10 Jay Pharma Inc. Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancer
ES2973731T3 (es) 2018-04-09 2024-06-24 Portland Tech Holdings Llc Extracto de cáñamo para el tratamiento del dolor en animales
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
WO2020012315A1 (en) * 2018-07-08 2020-01-16 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid composition for treatment of male subjects
EP3666765A1 (en) * 2018-12-11 2020-06-17 Emerald Health Biotechnology España,S.L.U. Chromenic phytocannabinoids, their synthesis and use in treatment or prevention of disease
EP3893868A4 (en) * 2018-12-12 2022-08-10 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN T-CELL LYMPHOMA (CTCL)
CA3128054A1 (en) * 2019-01-31 2020-08-06 Cava Healthcare Inc. Compounds for increasing mhc-i expression and modulating histone deacetylase activity
NL2022614B1 (en) * 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical, phyto-cannabinoid based compositions
KR20210151816A (ko) 2019-03-12 2021-12-14 이피엠 (아이피), 인코포레이티드 칸나비노이드 산 에스테르 조성물 및 이의 용도
EP3946307A4 (en) * 2019-04-02 2022-12-14 Ulagaraj Selvaraj SOLID NANOPARTICLE FORMULATION OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING AND IMMEDIATE DRUG RELEASE AFTER INTRAVENOUS ADMINISTRATION
US12178797B2 (en) 2019-05-03 2024-12-31 Zyus Life Sciences Inc. Formulation for pain management
US12220396B2 (en) 2019-05-03 2025-02-11 Zyus Life Sciences Inc. Formulation for pain management
AU2020268218B2 (en) * 2019-05-03 2022-09-08 Zyus Life Sciences Inc. Formulation for pain management
CN114096241A (zh) * 2019-05-16 2022-02-25 技术研究及发展基金有限公司 大麻素及其用途
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CN111184710A (zh) * 2020-03-02 2020-05-22 福建省中科生物股份有限公司 一种环酚的应用和制备方法
CA3175684A1 (en) 2020-04-29 2021-11-04 Jon Penarando Saez Cannabinoids for use in supressing cancer stem cells
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
WO2022016269A1 (en) * 2020-07-22 2022-01-27 The University Of British Columbia Silver enhanced cannabinoid antibiotics
EP4203925A1 (en) * 2020-08-31 2023-07-05 Nelson Mandela University Cannabinoid combinations and their use in the treatment of cancer
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
IL303553A (en) * 2020-12-08 2023-08-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of urothelial cancer
EP4319741A4 (en) * 2021-04-05 2025-04-23 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
KR20240116462A (ko) 2021-10-26 2024-07-29 더 유니버시티 오브 뉴캐슬 대마 추출물로 난소암을 치료하는 방법
AU2022379618A1 (en) 2021-10-26 2024-05-23 Dove Innovation Pty Limited Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
CA3235077A1 (en) 2021-10-26 2023-05-04 Alex Nance Systems and methods for producing hemp extracts and compositions
WO2023130160A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda).
WO2023130161A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2023161921A2 (en) * 2022-02-23 2023-08-31 Cannabotech Ltd. Compositions for use as an adjunctive therapy in the treatment of breast cancer
WO2023239415A1 (en) * 2022-06-08 2023-12-14 Angrow Company Limited Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject
WO2023238114A1 (en) * 2022-06-08 2023-12-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Combinations and methods for the treatment of cancer
WO2024082014A1 (en) * 2022-10-21 2024-04-25 Dolce Cann Global Pty Ltd Compositions comprising cannabidiolic acid and fatty acids
US12097211B2 (en) 2022-10-26 2024-09-24 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract
US12011451B2 (en) 2022-10-26 2024-06-18 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482917A1 (en) * 2002-02-01 2004-12-08 GW Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB2434312A (en) * 2006-01-18 2007-07-25 Gw Pharma Ltd Cannabinoid extracts for treating neurodegeneration
US20080103193A1 (en) * 2006-10-26 2008-05-01 Trevor Percival Castor Methods for making compositions and compositions for treating pain and cachexia
WO2008107878A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2449691A (en) * 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
EP2044935A1 (en) * 2007-10-02 2009-04-08 Vivacell Biotechnology Espana S.L. A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2460672A (en) * 2008-06-04 2009-12-09 Gw Pharma Ltd Cancer medication using cannabinoids in combination with non-cannabinoids
WO2009147439A1 (en) * 2008-06-04 2009-12-10 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2238707A (en) 1989-12-08 1991-06-12 Peter Bullock Repairing footwear
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US20040039048A1 (en) 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
ES2164584A1 (es) 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
ES1045342Y (es) 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
EP1326996A4 (en) 2000-09-14 2005-08-24 Univ California ID-1 AND ID-2 GENES AND PRODUCTS AS DIAGNOSTIC OR PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR THE TREATMENT OF BREAST CANCER AND OTHER TYPES OF CARCINOMA
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2380129B (en) 2001-02-14 2004-08-11 Gw Pharma Ltd Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
US20080057117A1 (en) 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
AU2002326312A1 (en) 2002-04-25 2003-11-10 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2391865B (en) 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
EP1907444B1 (en) 2005-04-01 2009-08-19 Intezyne Technologies Incorporated Polymeric micelles for drug delivery
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
BRPI0610364A2 (pt) 2005-05-13 2010-06-15 Unimed Pharmaceuticals Inc tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482917A1 (en) * 2002-02-01 2004-12-08 GW Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB2434312A (en) * 2006-01-18 2007-07-25 Gw Pharma Ltd Cannabinoid extracts for treating neurodegeneration
US20080103193A1 (en) * 2006-10-26 2008-05-01 Trevor Percival Castor Methods for making compositions and compositions for treating pain and cachexia
WO2008107878A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2449691A (en) * 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
EP2044935A1 (en) * 2007-10-02 2009-04-08 Vivacell Biotechnology Espana S.L. A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2460672A (en) * 2008-06-04 2009-12-09 Gw Pharma Ltd Cancer medication using cannabinoids in combination with non-cannabinoids
WO2009147439A1 (en) * 2008-06-04 2009-12-10 Gw Pharma Limited Anti-tumoural effects of cannabinoid combinations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Izzo, A. A. et al., "Cannabinoids in intestinal inflammation and cancer", 2009, Pharmacological Research, Vol. 60, pages 117 to 125. See in particular pages 122 and 123. *
Ligresti, A. et al, "Antitumour activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma", Journal of Pharmacology and Experimental Therapeutics, 2006, Vol. 318, pages 1375 to 1387. See abstract. *
Ligresti, A. et al. "Antitumour activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma", 2006, Journal of Pharmacology and Experimental Therapeutics, Vol 318, pages 1375-1387. *
Ligresti, A. et al., "Antitumour activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma", 2006, The Journal of Pharmacology and Experimental Therapeutics, Vol. 318, pages 1375 to 1387. See in particular pages 1378 and 1379. *
Miyato H. et al, "Pharmacological synergism between cannabinoids and Paclitaxel in gastric cancer cell lines", 2009, Vol. 155, pages 40 to 47. See in particular the "Discussion" at pages 44 to 46. *

Also Published As

Publication number Publication date
AR080454A1 (es) 2012-04-11
CY1117451T1 (el) 2017-04-26
TWI461205B (zh) 2014-11-21
US20130059018A1 (en) 2013-03-07
NZ602953A (en) 2014-09-26
WO2011110866A1 (en) 2011-09-15
ZA201207574B (en) 2014-09-25
MX2012010512A (es) 2012-10-15
CA2792722A1 (en) 2011-09-15
AU2018217273B2 (en) 2020-03-12
JP2013522184A (ja) 2013-06-13
GB2478595A (en) 2011-09-14
CO6630103A2 (es) 2013-03-01
ES2569669T3 (es) 2016-05-12
AU2016266059A1 (en) 2016-12-22
EP2544682A1 (en) 2013-01-16
UA109271C2 (uk) 2015-08-10
US20180042975A1 (en) 2018-02-15
US8790719B2 (en) 2014-07-29
EA201290901A1 (ru) 2013-04-30
TW201201828A (en) 2012-01-16
HUE029817T2 (en) 2017-04-28
PH12012501782A1 (en) 2012-11-12
IL221871A (en) 2017-03-30
AU2011225837A1 (en) 2012-11-01
PL2544682T3 (pl) 2016-08-31
CN102869356A (zh) 2013-01-09
BR112012023017A2 (pt) 2016-05-31
AU2018217273A1 (en) 2018-08-30
JP5785569B2 (ja) 2015-09-30
HRP20160427T1 (hr) 2016-07-01
SI2544682T1 (sl) 2016-06-30
DK2544682T3 (en) 2016-05-09
EP2544682B1 (en) 2016-02-10
US9675654B2 (en) 2017-06-13
US20150086653A1 (en) 2015-03-26
NZ629136A (en) 2016-03-31
KR20130067248A (ko) 2013-06-21
GB201004137D0 (en) 2010-04-28
SG184016A1 (en) 2012-10-30
BR112012023017A8 (pt) 2018-04-03

Similar Documents

Publication Publication Date Title
GB2478595B (en) Phytocannabinoids in the treatment of glioma
PL2652193T3 (pl) Obróbka
IL221511A (en) Arilatriazolones associated with bis aryl and their use
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201208173B (en) Peptices and their use
GB201120993D0 (en) Novel compounds and their use in therapy
EP2521569A4 (en) COMBINATION THERAPY WITH VB-201
PH12013500022A1 (en) Surface treatment
ZA201303773B (en) Compounds and their use
AP3665A (en) Water treatment
HUE041512T2 (hu) Új kombináció és alkalmazás
ZA201208454B (en) Use of diatomaceous earth in the pharmaceutocal industry
EP2560677A4 (en) COLD TREATMENT
GB201011411D0 (en) Therapeutic compounds and their use
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB201013573D0 (en) Treatment
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201016486D0 (en) Compounds for the use in treatment of plants
GB201014097D0 (en) Treatment
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB2483219B (en) Surface Treatment
GB201021319D0 (en) Treatment
GB201013068D0 (en) Liquid treatment

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20170511 AND 20170517

S73 Revocation on comptroller's initiative (section 73/patents act 1977)

Free format text: PATENT REVOKED; PATENT REVOKED UNDER SECTION 73(2) ON 23 APRIL 2019